Clinical Trial Update: Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing immunogenicity and safety of the Japanese Encephalitis vaccine IC51 (IXIARO, JESPECT) in a pediatric population residing in non-endemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Encephalitis

Drugs mentioned

• IC51 (IXIARO, JESPECT)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2014-12-19